

ISO 13022:2012-04 (E)

Medical products containing viable human cells - Application of risk management and requirements for processing practices

Contents		Page
Foreword		iv
Introduction		v
1	Scope	1
2	Normative references	2
3	Terms and definitions	2
4	Risk management process	6
4.1	General	6
4.2	Hazards associated with the cellular component	6
4.3	Risk analysis	8
4.4	Risk evaluation	9
4.5	Risk control	9
4.6	Evaluation of overall residual risk acceptability	9
4.7	Production and post-production information system	10
Annex B (informative)	Graphic representation of the part of the risk management process for cell-based medical products	12
Annex C (normative)	Requirements for donor selection and testing	13
Annex D (informative)	Guidance for tissue procurement	17
Annex E (normative)	Requirements for handling of cells and tissue during manufacture	20
Annex F (normative)	Requirements for packaging and labelling	23
Annex G (informative)	Guidance for transport	26
Annex H (informative)	Guidance for storage	31
Annex I (normative)	Requirements for traceability	34
Annex J (normative)	Risk reduction measures relating to contamination with viruses and other infectious agents such as TSE	35
Annex K (informative)	Guidance relating to hazards caused by the tumorigenic potential of human cells or tissues used for the production of medical products	38
Annex L (informative)	Guidance relating to microbiological contamination	39
Annex M (informative)	Guidance relating to potential adverse effects of non-cellular residues of the product	40
Annex N (normative)	Requirements relating to potential adverse effects of the cellular components of a medical product	41

Annex O (informative) Guidance for the characterization of the cellular components of a medical product	42
Annex P (informative) Clinical evaluation and testing	45
Bibliography	46